A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)

The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: * Histologically confirmed B-cell malignancy: * Chronic lymphocytic leukemia (CLL) * Small lymphocytic lymphoma (SLL) * Waldenström's macroglobulinemia (WM), * Lymphoplasmacytic lymphoma (LPL) * Other B-cell neoplasm * Failed or intolerant to either at least 2 prior regimens given in combination or sequentially OR have received 1 prior Bruton's tyrosine kinase (BTK)-containing regimen when a BTK inhibitor is approved as first line therapy * Have the ability to swallow and retain oral medication * Is Japanese Exclusion Criteria: * Active Hepatitis B virus (HBV)/Hepatitis C virus (HCV) infection at study entry * History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years * Known history of human immunodeficiency virus (HIV) infection * Clinically significant gastrointestinal abnormalities that might alter absorption (eg, gastric bypass surgery, gastrectomy) * Underlying history of severe bleeding disorders * History or concurrent condition of pneumonitis/interstitial lung disease